4576
D.Western Therapeutics Institute, Inc.
デ・ウエスタン・セラピテクス研究所
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Dec 2021
414,424
Dec 2022
448,100
Dec 2023
428,364
Dec 2024
471,580
Dec 2025
387,620
Operating profit(thousand JPY)
Dec 2021
-171,649
Dec 2022
-305,912
Dec 2023
-798,558
Dec 2024
-1,209,598
Dec 2025
-619,870
Operating profit margin(%)
Dec 2021
-41.42
Dec 2022
-68.27
Dec 2023
-186.42
Dec 2024
-256.5
Dec 2025
-159.92
Profit before tax(thousand JPY)
Dec 2021
-159,711
Dec 2022
-440,267
Dec 2023
-826,803
Dec 2024
-1,288,709
Dec 2025
-630,491
Profit(thousand JPY)
Dec 2021
-148,995
Dec 2022
-429,685
Dec 2023
-812,411
Dec 2024
-1,290,305
Dec 2025
-632,087
Total assets(thousand JPY)
Dec 2021
2,462,860
Dec 2022
2,956,376
Dec 2023
2,373,371
Dec 2024
1,669,444
Dec 2025
2,169,461
Cash and cash equivalents(thousand JPY)
Dec 2021
1,933,743
Dec 2022
2,334,668
Dec 2023
1,867,264
Dec 2024
1,126,035
Dec 2025
1,709,790
Cash flows from operating activities(thousand JPY)
Dec 2021
-176,306
Dec 2022
-354,770
Dec 2023
-586,821
Dec 2024
-1,299,118
Dec 2025
-493,794
Cash flows from investing activities(thousand JPY)
Dec 2021
-111,150
Dec 2022
-139,890
Dec 2023
-15,254
Dec 2024
-10,005
Dec 2025
-2,447
Cash flows from financing activities(thousand JPY)
Dec 2021
-104,459
Dec 2022
867,297
Dec 2023
134,466
Dec 2024
567,628
Dec 2025
1,080,014
Return on equity(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
81.4
Dec 2022
62.8
Dec 2023
53.9
Dec 2024
43.9
Dec 2025
66.1
Earnings per share(JPY per share)
Dec 2021
-5.08
Dec 2022
-14.5
Dec 2023
-25.56
Dec 2024
-36.74
Dec 2025
-13.19
Net assets per share(JPY per share)
Dec 2021
68.27
Dec 2022
60.14
Dec 2023
39.81
Dec 2024
17.59
Dec 2025
26.44
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.